The present invention relates to crystalline forms of compounds represented by structural formula I and compositions including crystalline forms of compounds represented by structural formula I described herein.The crystalline form of the compound with structural formula I and the composition including the crystalline form of the compound with structural formula I provided herein, especially the single crystalline form a, can be incorporated into the pharmaceutical composition, which can be used to treat various disorders (including cancer) related to the activity of CRM1.Methods for the preparation of compounds with structural formula I and their single crystalline forms are also described.本發明涉及由結構式I表示的化合物的結晶形式，以及包括本文所述的由結構式I表示的化合物的結晶形式的組合物。可以將具有結構式I的化合物的結晶形式和包括本文提供的具有結構式I的化合物的結晶形式的組合物，特別是單個結晶形式A摻入到藥物組合物中，該藥物組合物可以用於治療與CRM1活性相關的各種紊亂（包括癌症）。本文還描述了用於製備具有結構式I的化合物及其單個結晶形式的方法。
